John P. Schmid
Director at AnaptysBio; Director at Xeris Biopharma Holdings; Director at First Tracks Biotherapeutics. Based in San Diego, California.
- Rank
- 11066th of 14,644
- Companies held
- 6
- Largest holding
- ANAB, 35.2% of total
- Latest SEC filing
- Aug 10, 2026
What the $7.3M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings XERS Common Stock | Directly | 113,159 | $16.62 | $1.9M | 25.7% | Form 4, Aug 12, 2024 |
| AnaptysBio ANAB Common Stock | Directly | 37,652 | $47.40 | $1.8M | 24.4% | Form 4, Jun 15, 2026 |
| First Tracks Biotherapeutics TRAX Common Stock | Directly | 37,652 | $44.46 | $1.7M | 22.9% | Form 4, Jun 15, 2026 |
| AnaptysBio ANAB Common Stock | Through ESOP | 16,602 split-adjusted | $47.40 | $787K | 10.8% | Form 4, Jun 15, 2025 |
| Xeris Biopharma Holdings XERS Common Stock | By: The Schmid Family Trust dated August 15, 2017 | 25,200 | $16.62 | $419K | 5.7% | Form 4, Aug 12, 2024 |
| Design Therapeutics DSGN Common Stock | Directly | 30,674 | $9.32 | $286K | 3.9% | Form 4, Mar 22, 2024 |
| Design Therapeutics DSGN Common Stock | Through Schmid Family Trust U/A dated 8-15-17 | 26,965 | $9.32 | $251K | 3.4% | Form 4, Mar 25, 2024 |
| BlossomHill Therapeutics BLSM Common Stock | Directly | 6,000 | $14.41 | $86K | 1.2% | Form 4, Aug 10, 2026 |
| Design Therapeutics DSGN Common Stock | Through Schmid Family Trust U/A dated 8-15-17 | 9,156 | $9.32 | $85K | 1.2% | Form 4, Mar 22, 2024 |
| BridgeBio Oncology Therapeutics BBOT Common Stock | Directly | 30,000 | $1.86 | $56K | 0.8% | Form 4, Aug 11, 2025 |
Share counts are the amounts John P. Schmid reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 11063 | Daniel J. Phelan Director, TE Connectivity. Berwyn, PA | $7.3M |
| 11064 | Anthony M. Santomero Director, RenaissanceRe Holdings | $7.3M |
| 11065 | Gregory C. Toczydlowski EVP & President, Business Ins., The Travelers Companies. St. Paul, MN | $7.3M |
| 11066 | John P. Schmid Director, AnaptysBio. San Diego, CA | $7.3M |
| 11067 | Thomas C. Popeck CEO, Henry Schein Products, Henry Schein. Melville, NY | $7.3M |
| 11068 | Melissa Werneck EVP & Global Chief People Ofcr, The Kraft Heinz. Charlotte, NC | $7.3M |
| 11069 | David W. Osborne Chief Technical Officer, Arcutis Biotherapeutics. Westlake Village, CA | $7.3M |
Other AnaptysBio insiders
All ANAB insiders- Daniel Faga$35.3MPresident, CEO. #2928 overall
Questions
How much stock does John P. Schmid own?
John P. Schmid holds $7,309,963 in listed stock based on SEC filings and current prices, mostly Xeris Biopharma Holdings (XERS). That ranks 11066th on the Stock Rich List.
Is this John P. Schmid's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did John P. Schmid last buy or sell stock?
The most recent open-market trade on file is a purchase of 6,000 BLSM shares on Aug 10, 2026 at $16.00.